The Role of Serum Tetranectin, CA 125, and a Combined Index as Tumor Markers in Women with Pelvic Tumors

Serum tetranectin (Se-TN) and CA-125 were measured in 315 patients with a pelvic tumor and 458 healthy females. At a false-positive rate of 0.7% the sensitivity for ovarian cancer stage 1 and 2 was 33% for Se-TN and 76% for both CA 125 and an index based on Se-TN and CA 125 (Index 1). At a false-pos...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 1995-01, Vol.56 (1), p.22-28
Main Authors: Høgdall, Claus K., Mogensen, Ole, Tabor, Ann, Mogensen, Bent, Jakobsen, Anders K.M., Nørgaard-Pedersen, Bent, Larsen, Severin O., Clemmensen, Inge
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Biomarkers, Tumor - blood
Blood Proteins - analysis
CA-125 Antigen - blood
Enzyme-Linked Immunosorbent Assay
False Positive Reactions
Female
Female genital diseases
Genital Neoplasms, Female - blood
Genital Neoplasms, Female - diagnosis
Genital Neoplasms, Female - pathology
Gynecology. Andrology. Obstetrics
Humans
Lectins, C-Type
Linear Models
Medical sciences
Middle Aged
Neoplasm Staging
Pelvic Neoplasms - blood
Pelvic Neoplasms - diagnosis
Pelvic Neoplasms - pathology
Sensitivity and Specificity
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Serum tetranectin (Se-TN) and CA-125 were measured in 315 patients with a pelvic tumor and 458 healthy females. At a false-positive rate of 0.7% the sensitivity for ovarian cancer stage 1 and 2 was 33% for Se-TN and 76% for both CA 125 and an index based on Se-TN and CA 125 (Index 1). At a false-positive rate of 0.4% the sensitivity was 29% for Se-TN, 62% for CA 125 (35 U/ml), and 76% for Index 1. A negative correlation was found between the Se-TN level and the stage of cancer. The sensitivity for benign tumors was 6% for Se-TN, 17% for CA 125, and 21% for Index 1 at a false-positive rate of 0.4%. In the present study the sensitivity and specificity levels of Se-TN were not sufficiently high to warrant the use of Se-TN as an individual marker for ovarian cancer. The sensitivity rose with the index-based Se-TN and CA 125 without causing a concomitant increase in the rate of false-positive results. None of the markers rose to levels that would allow their use in clinical diagnosis to discriminate between localized cancer and benign tumors.
ISSN:0090-8258
1095-6859
DOI:10.1006/gyno.1995.1004